Wells Fargo lowered the firm’s price target on Sutro Biopharma (STRO) to $3 from $4 and keeps an Equal Weight rating on the shares. The firm remains on the sidelines given the early nature of Sutro’s clinical pipeline as management works to get its multiple ADC programs into the clinic. Shares are likely to remain range bound, Wells adds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STRO:
- Sutro Biopharma’s Strategic Shift and Pipeline Developments: A Hold Rating Amid Transitional Phase
- Sutro Biopharma Advances ADC Pipeline and Reports Q2 2025 Results
- Sutro Biopharma enters research collaboration with FDA for ADC standards
- Sutro Biopharma Faces NASDAQ Non-Compliance Notice
- Sutro, Sarepta, Incyte, Signet, Wix: Trending by Analysts